Hyundai, Takeda team up for TachoSil patch

Published: 2012-10-26 06:56:00

Updated: 2012-10-26 06:56:00

Hyundai Pharm announced Wednesday that it has signed an agreement with Takeda Pharmaceuticals Korea for the exclusive distribution right in Korea of TachoSil (absorbable fibrin sealant patch) for use as an adjunct to hemostasis in cardiovascular surgery.

In addition to Tachocomb patch, the enh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK